摘要：Methyl Bromide in the United States is supplied by only four firms (two producers and two importers) who reap windfall profits from MB restrictions. Since 1992 we estimate that over $300 million in cumulative windfall profits have resulted from restrictions on Methyl Bromide and currently run between $65 to $80 million annually. We examine the factors that influenced this price rise, the changes in quota premiums and deadweight losses under trade and no-trade scenarios; and how methods to capture and redistribute windfall profits will alter efficiency and equity.
